Overview

A Hepatic Impairment Study for PF-04965842.

Status:
Completed

Trial end date:
2019-04-30

Target enrollment:

Participant gender:

Summary

This is a Phase 1 non randomized, open label, single dose, parallel cohort study to investigate the effect of hepatic impairment on the PK, safety and tolerability of PF 04965842.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Abrocitinib